This is another one in the continued parade of good news. The level of capital commitments for gene and immuno therapy for solid tumors is on the rise - as is the level of competition for the grand prize. Lots of M&A activities, and most likely more to come. This will enable smaller outfits with specialized human capital to have a better access to private funding. This is nothing new, but it's great to see that the activities are snowballing.
I also found this article about CAR-T that describes the current limitations and approaches of the treatment for the solid tumors.
Lots to be hopeful about!!